Bisphosphonates linked to eye disease 5 Apr 2012 0 comments Patients starting on oral bisphosphonates are at increased risk of developing inflammatory eye disease, according to the largest study into the subject to date.
Diabetes drugs no fix for obesity 19 Jan 2012 0 comments Doctors should not rush to prescribe a newer class of diabetes drug off-label for weight loss, an expert says.
Gender reassignment assessment 'too haphazard' 24 Nov 2011 0 comments Women are undergoing sex changes in Australia with only "token" requirements for mental health assessment, a psychiatrist has warned.
HbA1c measure will cut diabetes cases 10 Nov 2011 0 comments The prevalence of diabetes could fall by as much as 30% when Australia makes the long-awaited move to diagnosis based on HbA1c, an expert says
MBS calls time on vertebroplasty rebates 20 Oct 2011 0 comments Following long-running controversy over the effectiveness of the procedure, vertebroplasty has been stripped of its public funding, Medicare has confirmed.
TGA issues pioglitazone-bladder cancer alert 21 Jul 2011 0 comments Patients taking pioglitazone should be vigilant for blood in the urine, the Therapeutic Goods Administration has warned, amid concern the drug may be linked to increased rates of bladder cancer.
Look for pancreatitis signs with newer diabetes drugs 14 Jul 2011 0 comments Diabetes patients taking exenatide or sitagliptin should be monitored closely for symptoms of pancreatitis, experts say.
No magic cure for distant diabetes care 7 Jul 2011 0 comments Skype is no magic bullet for bridging the urban-rural divide in diabetes care, research suggests, with technological teething problems hampering its uptake for video consults.
New guide to surgery in diabetes 30 Jun 2011 0 comments Elective surgery should be postponed in patients with diabetes if their HbA1C is higher than 9%, due to the risk of postoperative complications, Australian experts advise.
Experts question glucose emphasis 21 Apr 2011 0 comments Experts have hit out at what they say is an over-emphasis on intensive glucose lowering in type 2 diabetes guidelines, calling for the agenda to be broadened beyond glucose control alone.